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Smooth muscle cell (SMC) proliferation and fibrosis contribute to the development of advanced ather-
osclerotic lesions. Oxidative stress caused by increased production or unphysiological location of reactive
oxygen species (ROS) is a known major pathomechanism. However, in atherosclerosis, in particular
under hyperglycaemic/diabetic conditions, the hydrogen peroxide-producing NADPH oxidase type 4
(NOX4) is protective. Here we aim to elucidate the mechanisms underlying this paradoxical ather-
oprotection of vascular smooth muscle NOX4 under conditions of normo- and hyperglycaemia both
in vivo and ex vivo. Following 20-weeks of streptozotocin-induced diabetes, Apoe / mice showed a
reduction in SM-alpha-actin and calponin gene expression with concomitant increases in platelet-de-
rived growth factor (PDGF), osteopontin (OPN) and the extracellular matrix (ECM) protein fibronectin
when compared to non-diabetic controls. Genetic deletion of Nox4 (Nox4/Apoe /) exacerbated
diabetes-induced expression of PDGF, OPN, collagen I, and proliferation marker Ki67. Aortic SMCs iso-
lated from NOX4-deficient mice exhibited a dedifferentiated phenotype including loss of contractile gene
expression, increased proliferation and ECM production as well as elevated levels of NOX1-associated
ROS. Mechanistic studies revealed that elevated PDGF signalling in NOX4-deficient SMCs mediated the
loss of calponin and increase in fibronectin, while the upregulation of NOX1 was associated with the
increased expression of OPN and markers of proliferation. These findings demonstrate that NOX4 actively
regulates SMC pathophysiological responses in diabetic Apoe / mice and in primary mouse SMCs
through the activities of PDGF and NOX1.
& 2016 Elsevier Inc. All rights reserved.1. Introduction
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u.au (K.A.M. Jandeleit-Dahm).(NOX) enzymes are major contributors to oxidative stress and
redox signalling in the vasculature [1]. The NOX4 isoform con-
stitutively generates hydrogen peroxide (H2O2) that under non-
disease conditions is produced at tightly controlled levels in dis-
crete subcellular locations to mediate various physiological pro-
cesses in vascular cells including the maintenance of the con-
tractile phenotype in smooth muscle cells (SMCs) [2]. Pathological
activation of NOX enzymes, particularly NOX4 has been shown to
affect differentiation such as preadipocytes [3] and promote in-
flammation in various disease models, including osteoporosis and
vascular disease [4,5]. In the context of diabetes NOX enzymes are
known to play central roles in vascular disease progression [6].
Chronic hyperglycaemia as seen in type 1 diabetes accelerates the
progression of atherosclerosis from early to advanced lesions with
an increasing importance of cell types capable of extracellular
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demonstrated that atherosclerosis development can be modulated
in response to NOX4 deletion or overexpression. Whereby over-
expression of NOX4 results in a reduction in atherosclerosis [7],
while genetic deletion has been shown to increase atherosclerosis
development [8–10]. The high degree of plasticity exhibited by
vascular SMCs allows for a diversity of phenotypes in response to
chronic exposure to the diabetic milieu; however, the potential
role of NOX4 in this process remains relatively unexplored.
The significant contribution of vascular SMCs to atherosclerosis
plaque development has gained recent attention with the refine-
ment of approaches to identify [11] and track [12] phenotypically
modulated SMCs. SMC phenotype switching is characterised by a
loss of smooth muscle markers and a gain of proliferative and
synthetic activity mediated by factors such as PDGF and OPN [13–
15]. Interestingly, SMCs isolated and cultured from streptozotocin
(STZ)- diabetic rats show decreased SM-α-actin, elevated super-
oxide production, increased OPN expression and enhanced PDGF-
mediated proliferation [16,17], consistent with such a switch in the
SMC phenotype. Few studies have directly tested the effects of
high glucose (HG) on PDGF-BB expression; however, HG has been
shown to increase PDGF-BB receptor binding and downstream
signalling events [18]. Increased expression of OPN has also been
demonstrated in the medial layer of arteries from diabetic humans
and rodents [19]. Previous work by Lyle et al. [20] identified a link
between H2O2 and OPN expression in SMCs; however, this has not
yet been investigated in the context of diabetes.
Better understanding the role of NOX4 in SMC pathobiology
would provide greater insight into the controversial, and poten-
tially vasoprotective, role of NOX4 in diabetes-associated athero-
sclerotic disease. Therefore, we investigated the role of NOX4 in
vascular SMC fibrosis and proliferation in Apoe / mice 20-weeks
after STZ-induced diabetes and complemented these in vivo stu-
dies with additional mechanistic experiments in mouse aortic
SMCs with and without HG treatment.2. Materials and methods
2.1. Generation of experimental mice
All animal procedures were approved by the Alfred Medical
Research and Education Precinct (AMREP) Animal Ethics Com-
mittee in accordance with the National Health and Medical Re-
search Council of Australia guidelines. The animals were main-
tained on a 12-hour light/dark cycle with unrestricted access to
water and standard chow (Specialty Feeds, Glen Forrest, WA,
Australia) under pathogen-free conditions in the Precinct Animal
Centre of the Baker IDI Heart and Diabetes Institute. Nox4 / [21]
mice were backcrossed with Apoe / mice on the C57BL/6J
background (B6.129P2-Apoetm1Unc/J, Jax Labs, Bar Harbor, ME,
USA) for 10 generations to generate Nox4 /Apoe / double
knockout animals (Transnetyx, USA); as previously described in
[9]. Diabetes was induced in six-week-old Nox4 /Apoe / and
Nox4þ /þApoe / wildtype male mice by five daily i.p. injections of
streptozotocin [55 mg/kg dissolved in citrate buffer (Sigma-Al-
drich, St Louis, MO, USA)] [22]. Mice with a blood glucose level
Z15 mmol/L were deemed diabetic and included in the study.
After 20 weeks, the mice were killed by an i.p. injection of sodium
pentobarbital (100 mg/kg; Euthatal, Sigma-Aldrich, Castle Hill,
NSW, Australia).
2.2. Isolation and culture of primary aortic smooth muscle cells
(SMCs)
SMCs from mouse thoracic aortas (stripped of adventitia) wereisolated by enzymatic digestion and grown in DMEM with 10%
fetal bovine serum (FBS) as described previously [23]. Cells from
passages 4–8 were grown to 70–80% confluence for experiments,
unless otherwise specified.
2.3. Gene expression analysis by Quantitative RT-PCR
Total RNA was extracted from frozen aortas and SMCs using
TRIzol reagent (Invitrogen Australia, Mt Waverly, VIC, Australia)
and reversed transcribed to cDNA using the Superscript First
Strand Synthesis System (Life Technologies BRL, Grand Island, NY,
USA). Quantitative real-time PCRs were performed using a Taqman
system (ABI Prism 7500; Perkin-Elmer, Poster City, CA, USA) for
OPN, PDGFbb, fibronectin, collagen I, CTGF, TGFβ, PCNA and Nox1
and genes. The SYBR Green PCR Master Mix (Applied Biosystems,
Darmstadt, Germany) system was used for transgelin, calponin
and Ki67 genes. Probes and primers were designed using a Primer
Express program (primer sequences in Supplemental Table 1) and
purchased from Applied Biosystems (ABI, Foster City, CA, USA).
Gene expression was normalised relative to the housekeeping
gene, 18S ribosomal RNA (18S rRNA Taqman Control Reagent kit)
and expressed as fold inductions relative to wild-type non-diabetic
mice that were arbitrarily assigned a value of 1.
2.4. Western blot analyses
Protein lysates of whole aortas (n¼4–6/group) and whole cells
(average of 3–4 independent experiments) were prepared in
radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris,
150 mM NaCl, 5 mM EDTA, 0.05% SDS, 0.5% deoxycholate) with
fresh protease and phosphatase inhibitors (PMSF, aprotinin, leu-
peptin) as described previously [9,24]. For proteins secreted into
culture supernatant (fibronectin and collagen) proteins, SMC were
grown in DMEM 0.1% FBS supplemented with L-ascorbic acid and
beta-aminopropionitrile (50 mg /ml of each) for three days. Su-
pernatant proteins were concentrated via sequential centrifuga-
tion in Amicon Ultra Centrifugal Filters as per the manufacturers
instructions (Merck Millipore, Billerica, MA, USA). Concentration of
protein in all extracts was determined by Bradford Assay. Equal
amounts of protein diluted in Laemmli buffer were separated by
SDS-PAGE and transferred to a nitrocellulose membrane. All blots
were incubated with primary antibodies overnight at 4 °C and
secondary antibodies for 1 h at room temperature. Antibody de-
tails are outlined in Supplemental Table 2. SMC proteins were vi-
sualised by enhanced chemiluminescence (ECL, GE) and detected
with Amersham Hyperfilm ECL (GE), with band densitometry
performed using ImageJ software (National Institutes of Health,
Bethesda, MD). Aortic proteins were scanned by the Odyssey In-
frared Imaging System (LI-COR Biosciences) using the appropriate
channels and band intensity quantified using Quantity-One soft-
ware (Bio-Rad).
2.5. Circulating biomarkers
The concentrations of PDGF-BB and OPN were measured in
serum collected from mice 1 week prior to the experimental
endpoint. Frozen samples were sent to Aushion BioSystems (Bill-
erica, MA, USA) for quantification using the Circa™ Immunoassay
platform.
2.6. Immunohistochemical staining of atherosclerotic lesions
Paraffin-fixed sections (4 mm) of aorta were stained for markers
of fibrosis and proliferation: OPN, PDGF, SM-alpha-actin, fi-
bronectin, collagen I, and Ki67. Antibody dilutions and details are
outlined in Supplemental Table 3. De-paraffinized sections were
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endogenous peroxidase activity. Collagen I was unmasked by
pepsin digest. For this, sections were incubated in dH2O for 10 min
at 37 °C then transferred to a pepsin (1 mg/ml; #P6887, Sigma)-
0.2 N HCl solution for 10 min at for 37 °C followed by washes in
dH2O and PBS at room temperature. Sections were processed for
immunohistochemistry as described previously [25]. Non-specific
binding was blocked by incubation with 2.5% Normal Horse Serum
(Vector Laboratories, Burlingame, CA, USA) for 30 min at room
temperature. Primary antibodies were applied overnight incuba-
tion at 4 °C in a humidified chamber. Sequential blocks of Avidin
and Biotin (Vector Laboratories) were followed by incubation with
the appropriate biotinylated secondary antibody (Vector Labora-
tories) for 30 min. All sections were incubated with horseradish
peroxidase-conjugated streptavidin (Vectastain Elite ABC Staining
Kit; Vector Laboratories), visualised with 3,3′-diamino-benzidine
tetrahydrochloride/H2O2 (DAB; Sigma-Aldrich, St Louis, MO, USA)
and counterstained with Mayer's haematoxylin prior to mounting
with DePex. Images were captured on a light microscope and di-
gitized with a high-resolution camera (Olympus BX-50; Olympus
Optical) at x10 magnification and quantified in a blinded manner
(Image-Pro Plus; v6.0). Results represent positively stained area as
a percentage of the total aorta area. Positive staining for Ki67 was
expressed per aortic medial area (excluding plaque).
2.7. Immunocytochemical staining of MASMs
Vascular SMCs were grown on glass coverslips at 100,000 cells/
well (in a 6-well plate), with each condition in triplicate. Cells
were processed as previously described [26]. In short, cell were
quickly washed with PBS, fixed with 10% formaldehyde for 10 min,
rinsed with dH2O and permeabilized with 0.5% Triton-X-100 in
PBS for 5 min. After blocking in filtered 3% bovine serum albumin
for 1 h, cells were incubated with anti-OPN (1:100; see Supple-
mental Table III) overnight at 4 °C and then incubated with
fluorophore-conjugated secondary antibody for 1 h at room tem-
perature. After repeated washes in dH2O, stained cells were
mounted in ProLong Gold Antifade Reagent (InVitrogen #P-36931)
containing 4′, 6-diamidino-2-phenylindole (DAPI) for nuclei
staining. Images were acquired with a Zeiss LSM 510 META Laser
Scanning Confocal Microscope System using a 40 oil objective
lens and Zeiss ZEN acquisition software. Threshold settings of the
confocal microscope remained constant. Controls with no primary
or secondary antibody showed no fluorescence. The images are
maximum intensity projections of Z-series from the base through
the top of the cell.
2.8. Growth curve
MASM cells at passage 6 were seeded at 30,000 cells per well
into a 6 well plate; n¼3 per condition. At 24, 48, 72 and 96 h after
seeding cells were trypsinised, stained with trypan blue and live
cells counted by haemocytometer. Data from the 72-hr time point
are presented.
2.9. Reactive oxygen species measurements
2.9.1. Amplex red (hydrogen peroxide)
Hydrogen peroxide was measured in SMCs using the Amplex
red commercial kit following the manufacturer's instructions
(Molecular Probes, Eugene, OR, USA). In short, SMCs seeded in
6 well plates were exposed to high glucose (25 mM) or normal
glucose DMEM (10% FBS) for 2 days prior to protein harvest.
Twenty microliters of whole cell isolate, standards and blank were
assayed in triplicate in black 96-well plates after addition of pre-
warmed (37 °C) working solution containing 100 mM Amplex redreagent and 0.2 U/ml horseradish peroxidase. Fluorescence in-
tensity was measured in 30-minute intervals at 37 °C on a Victor
fluorescence microplate reader at 544 nm excitation/590 nm
emission. Data from the 120-min time point are presented as
mmol of hydrogen peroxide standardized to protein concentration.
2.9.2. L-012 (superoxide)
MASM cells were seeded at 20,000 cells per well into black 96-
well microplates; n¼6 per condition. After 24 h, wells were wa-
shed with pre-warmed Krebs-HEPES and incubated with 100 ml of
Krebs-HEPES supplemented with L-012 (Wako Chemicals, Virginia,
USA) at a concentration of 100 mM at 37 °C for 15 min. Chemilu-
minescence was recorded every 5 min for 60 min at 37 °C on a
luminometer (Berthold Technologies, Germany). Data from the 45-
minute time point are presented. In experiments with NOX in-
hibition, Nox4 /Apoe / SMCs were prepared in 96-well plates
(as outlined above) and treated with the NOX1/NOX4 dual in-
hibitor GKT137831 (1 mM/ml) prior to the addition of L-012.
2.10. PDGF-BB treatment and inhibition studies
Cells were seeded at 50,000 cells/well in 6 well plates and al-
lowed to adhere overnight before serum deprivation for 48 h in
0.1% FBS DMEM. Prior to treatment, PDGF and anti-PDGF neu-
tralising antibody were incubated for 1 h at 37 °C. Nox4þ /
þApoE / SMCs were treated with the PDGF-BB (10 ng/ml; Sigma
#P 4306, Saint Louis, MO, USA) and inhibitor (67 mM/ml; Merck-
Millipore #06-127, Temecula, CA, USA) cocktail while Nox4 /
Apoe / SMCs were treated with PDGF inhibitor (67 μg/ml)
alone for 24 h. In experiments with PDGF-BB and PDGF inhibitor
treatments, subconfluent MASMs were made quiescent in DMEM
with 0.1% fetal bovine serum for 48 h prior to treatment with PDGF
(10 ng/ml) with or without PDGF neutralising antibody (67 mM/ml)
for 24 h.2.11. Nox1 silencing
The knockdown of Nox1 in primary mouse aortic SMCs was
achieved by transfection with siRNA directed against mouse Nox1
(NM_172203) (Mm_Nox1_3 FlexiTube siRNA, Qiagen, Valencia, CA,
USA). SMCs were seeded at 200,000 cells/60-mm dish. The fol-
lowing day, non-target control (AllStars Negative Control siRNA,
Qiagen) or siRNA against Nox1 were incubated separately with
Lipofectamine RNAiMAX reagent (7.5 ml/ well; Life Technologies,
Carlsbad, CA) in Opti-MEM (Life Technologies) for 10 min. Cells
were equilibrated with warmed Opti-MEM prior to the addition of
non-target or Nox1 siRNA mixture (final concentration of 10 nM/
well). Treatment conditions were replicated in triplicate. After
overnight of incubation with siRNA, the medium was replaced
with fresh DMEM with 0.1% FBS. Cells were harvested for RNA
isolation 2 days after transfection. The knockdown efficiency in
Nox4þ /þApoe / SMCs was verified by qRT-PCR to be greater than
50% for Nox1 mRNA.2.12. H2O2 treatment
SMCs were treated with H2O2 to assess the H2O2-dependent
effects of Nox4 deletion. After 48 h of exposure to normal or high
glucose media in T75 flasks, cells were trypsinized and seeded at
200,000 cells/well in 6 well plate. The following day, SMCs were
treated with H2O2 (100 mM; BSPA5.500, LabServ Thermo Fisher
Scientific Australia) for 4 h and harvested immediately for RNA
extraction. Each condition was repeated in triplicate.
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All data are presented as mean 7 SEM. Groups were analysed
by one-way and two-way ANOVA with an LSD post hoc test for
multiple comparison of the means using SPSS Statistics version 22
(IBM, St Leonards, NSW, Australia). A p value of o0.05 was con-
sidered statistically significant.3. Results
3.1. Altered SMC phenotypic marker expression in the aortas from
diabetic NOX4-deficient mice
The effects of diabetes and NOX4 on characteristic markers of
the SMC phenotype were first assessed in vivo using aortas from
non-diabetic and diabetic wildtype (Nox4þ /þApoe /) and double
knockout (Nox4 /Apoe /) mice. Diabetes was associated with
reduced aortic gene expression of the hallmark SMC contractility
markers, SM-α-actin and calponin (Fig. 1A, left panels). Lack of
NOX4 also reduced SM-α-actin and calponin in non-diabetic mice
while further reducing SM-α-actin in diabetic mice when com-
pared to Nox4þ /þApoe / counterparts. The mediators of SMC
phenotype switching, PDGF-BB and OPN, were elevated in diabetic
mouse aorta (Fig. 1A, right panels). Furthermore, NOX4 deficiencyFig. 1. Downregulation of contractile SMC markers with concomitant upregulation o
(A) mRNA levels of SM-α-actin, calponin, PDGF-BB, and OPN relative to 18S in aortas from
bars) mice measured by quantitative real time polymerase chain reaction (qRT-PCR).
staining in medial layer of aortas from Nox4þ /þApoe / and NOX4 /Apoe / mice;
expression in aortas from Nox4þ /þApoe / and NOX4 /Apoe / mice as assessed by (C
the β-actin level. (E) Circulating levels of PDGF-BB protein in the serum from NOX4-defimarkedly increased both PDGF-BB gene and protein expression in
the diabetic setting (Fig. 1A and B). In contrast, only diabetic
Nox4 /Apoe / mice showed increased aortic OPN gene (Fig. 1A,
right panel) and protein levels (Fig. 1D). Consistent with ob-
servations in the aorta, NOX4-deficient mice displayed increased
circulating levels of PDGF (Fig. 1E, left panel). Serum OPN levels
were increased in response to diabetes in Nox4þ /þApoe / mice
and basally by NOX4 deficiency in non-diabetic mice (Fig. 1E, right
panel and Supplementary Fig. 1). These data suggest that both
diabetes and NOX4 modulate the expression of contractility genes
and PDGF-BB in the aorta and circulation. In contrast, regulation of
aortic OPN expression by NOX4 is only apparent in the context of
diabetes.
3.2. Expression of fibrosis and proliferation is increased in NOX4-
deficient SMCs
We next investigated responses downstream of PDGF and OPN
signalling in SMCs involved in atherosclerotic plaque develop-
ment, fibrosis and proliferation. Diabetes induced expression of
the extracellular matrix (ECM) protein fibronectin in the aortas of
Nox4þ /þApoe / and Nox4 /Apoe / mice (Fig. 2A). An addi-
tional fibrosis marker Collagen I was only upregulated in Nox4 /
Apoe / mice with diabetes (Fig. 2B). Similarly, expression of the
proliferative marker Ki67 followed a trend to increase in diabeticf PDGF-BB and osteopontin (OPN) in aortas from diabetic NOX4-deficient mice.
NOX4-deficient (Nox4þ /þApoe / , filled bars) and control (NOX4-/-Apoe / , open
(B) Representative immunohistochemistry images and analysis showing PDGF-BB
Brown: PDGF-BB, blue: nuclear counterstaining with Hematoxylin. OPN protein
) immunohistochemistry and (D) immunoblotting with fold changes normalised to
cient mice compared to control mice. Values are mean7SEM (n¼6–8). *po0.05.
Fig. 2. Elevated expression of fibrosis and proliferation markers in the aortas from diabetic NOX4-deficient mice. Representative images and analysis (right) of im-
munohistochemical staining for (A) Fibronectin, (B) Collagen I and (C) Ki67 in the aortas of Nox4þ /þApoe / (filled bars) and Nox4 /Apoe / (open bars) mice. Values are
mean positively stained area7SEM (n¼6). *po0.05.
Fig. 3. Lack of NOX4 decreases expression of SMC contractility markers in association with marked increases in PDGF-BB and osteopontin (OPN) in mouse aorta SMCs.
(A) Relative SM-α-actin, transgelin and calponin mRNA levels in SMCs derived from Nox4þ /þApoe / (filled bars) and Nox4 /Apoe / (open bars) mouse aortas cultured in
normal (NG) and high glucose (HG) conditions. (B) Immunoblotting of calponin protein in Nox4þ /þApoe / (denoted Nox4þ /þ) and Nox4 /Apoe / (denoted Nox4-/-)
SMCs. (C) PDGF-BB and OPN gene expression as well as OPN protein expression as shown by immunoblotting (D) and immunocytochemistry (E). Analysis of immunoblots
represents fold changes from Nox4þ /þApoe /– SMCs cultured under NG conditions normalised to the β-tubulin level (n¼4). Immunocytochemistry images show Red:
nuclear DAPI staining and Green: OPN, magnification 40. *po0.05.
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NOX4 in the suppression of Collagen I and potentially Ki67 ex-
pression in the vasculature exposed to the diabetic milieu.
3.3. Enhanced PDGF-BB and osteopontin (OPN) expression in NOX4-
deficient SMCs
To study the potential mechanisms underpinning NOX4- and
diabetes- mediated SMC phenotype modulation, we isolated aortic
SMCs from Nox4þ /þApoe / and Nox4 /Apoe / mice and cul-
tured these cells under normal glucose (NG; 5.5 mM) and high
glucose (HG; 25 mM) conditions. In contrast to the reduced con-
tractile gene expression seen in whole aortas from diabetic mice,
treatment of SMCs with HG did not alter SM-alpha-actin expres-
sion and led to a slight elevation in both transgelin and calponin
mRNA levels (Fig. 3A). Consistent with the in vivo studies, NOX4
deficiency significantly decreased contractile gene expression
(Fig. 3A) as well as calponin protein expression (Fig. 3B), further
supporting a prominent role for NOX4 in the maintenance of SMC
phenotype. Treatment of Nox4þ /þApoe / SMCs with HG did not
mirror the effects of diabetes on aortic PDGF and OPN gene ex-
pression. However, consistent with our in vivo findings in
Nox4 /Apoe/ aortas, SMCs from these Nox4 /Apoe / mice
displayed heightened expression of PDGF and OPN (Fig. 3C).
Moreover, only Nox4-/-Apoe / SMCs cultured under HG condi-
tions demonstrated a small increase in OPN protein expression
(Fig. 3D) and a distinct intracellular OPN distribution pattern when
compared to Nox4þ /þApoe / SMCs (Fig. 3E). These observations
further support a unique function of NOX4 on OPN protein ex-
pression in the setting of HG.Fig. 4. Upregulation of fibrosis and proliferation markers in SMCs from NOX4-deficient
and collagen I as well as profibrotic mediators transforming growth factor (TGF)-β and co
bars) and Nox4 /Apoe / (open bars) aortas cultured in normal (NG) and high glucose
measured by immunoblotting culture media of Nox4þ /þApoe / (denoted Nox4þ /þ) and
Nox4þ /þApoe / SMCs. (D) Expression of proliferation genes PCNA and (E) growth cur3.4. Expression of fibrosis and proliferation markers in NOX4-defi-
cient SMCs
To explore the functional consequences of increased PDGF-BB
and OPN in NOX4- deficient SMCs, we evaluated markers of fi-
brosis and proliferation. Irrespective of the glucose concentration,
SMCs lacking NOX4 showed increased expression of genes en-
coding the ECM proteins fibronectin and Collagen I in addition to
the important pro-fibrotic factors TGFβ and CTGF (Fig. 4A). HG
treatment induced Collagen I gene expression in Nox4þ /þApoe /
and Nox4 /Apoe / cells to a similar extent. Analysis of ECM
proteins secreted into the culture media revealed a trend for in-
creased fibronectin production (Fig. 4B) combined with sig-
nificantly enhanced collagen production in Nox4 /Apoe / SMCs
(Fig. 4C). HG induced gene expression of the proliferation marker
Ki67, which was further elevated in Nox4 /Apoe / SMCs
(Fig. 4D, left panel). The additional proliferative marker PCNA was
unaffected by HG but markedly increased in SMCs lacking NOX4
(Fig. 4D, right panel). Growth curve analysis revealed an increase
in SMC proliferation under HG conditions, which was further in-
creased in those cells lacking NOX4 (Fig. 4E). Thus, aortic Ki67
mRNA levels mirrored the pro-proliferative effects of HG on SMCs
whereas PCNA more closely reflected the effect of NOX4. Taken
together, these findings demonstrate an important role for NOX4
in preventing SMC fibrosis and HG-mediated proliferation.3.5. NOX4 deficiency reduces hydrogen peroxide (H2O2) production
and increases superoxide (O2
) in high glucose-treated SMCs inmouse aortas. (A) Relative mRNA levels of extracellular matrix proteins fibronectin
nnective tissue growth factor (CTGF) in SMCs derived from Nox4þ /þApoe / (filled
(HG) conditions. Extracellular fibronectin (B) and collagen I (C) protein expression
Nox4 /Apoe / (denoted Nox4 /) SMCs with fold changes normalised to the NG
ve assessment of proliferation. Values are mean7SEM (n¼4–6). *po0.05.
Fig. 5. Reduced hydrogen peroxide and increased superoxide production associated with elevated Nox1 gene expression in high glucose treated NOX4-deficient SMCs.
(A) Hydrogen peroxide (A) and superoxide (B) production in SMCs from Nox4þ /þApoe / (filled bars) and Nox4 /Apoe / (open bars) aortas cultured under normal (NG)
and high glucose (HG) conditions as measured by Amplex Red and L012 chemiluminescence, respectively. (C) Expression of Nox1 gene relative to 18S. (D) Superoxide levels
in DKO cells treated with or without the NOX1/NOX4 dual inhibitor GKT137831. Values are mean7SEM (n¼6). *po0.05.
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The effect of NOX4 deletion on H2O2 and O2 production by
SMCs was measured via Amplex Red and LO12 chemilumines-
cence, respectively. Nox4 /Apoe / SMCs cultured under HG
conditions showed decreased H2O2 levels when compared to HG
treated Nox4þ /þApoe / SMCs (Fig. 5A). HG induced O2 pro-
duction in Nox4þ /þApoe / cells and to a greater extent in Nox4 /
Apoe / SMCs (Fig. 5B). We investigated whether the increase in
O2- was associated with compensatory upregulation of the other
prominent NOX isoform in vascular SMCs, NOX1. Indeed SMCs
from Nox4 /Apoe / mice showed dramatic increases in Nox1
gene expression compared to Nox4þ /þApoe / SMCs (Fig. 5C and
Supplemental Fig. 2A). mRNA levels of the NOX1 cytosolic orga-
nizer subunit NOXO1 were unchanged while activator subunit
NOXA1 was only detectable in Nox4 /Apoe / SMCs (Supple-
mental Fig. 2B and C). Lastly, treatment of Nox4 /Apoe / SMCs
with the NOX1/NOX4 dual inhibitor GKT137831 significantly re-
duced O2 levels (Fig. 5D) suggesting a role for NOX1 in O2
production in NOX4-deficient SMCs.
Next we conducted a series of experiments to dissect the re-
lative contributions of upregulated NOX1 and PDGF as well as the
loss of NOX4-derived H2O2 to the observed phenotypic phenom-
ena. According to our working hypothesis, the most upstream
perturbation of the signalling cascade was NOX4 deficiency fol-
lowed by elevated PDGF that acts as an upstream inducer of NOX1expression and activity.
3.6. Silencing of NOX1 attenuates the aberrant induction of PDGF-
BB, osteopontin (OPN), and pro-proliferative gene expression in
NOX4-deficient SMCs
NOX1 siRNA decreased gene expression of NOX1 in Nox4þ /
þApoe / SMCs by 50% (Fig. 6A; 1.070.008 to 0.4970.09). The
dramatic increase in NOX1 mRNA levels in NOX4-deficient SMCs
was significantly, albeit only modestly (12%), reduced by siRNA
treatment. Silencing of NOX1 reduced expression of PDGF-BB
(Fig. 6B) and OPN (Fig. 6C) in both Nox4þ /þApoe / and Nox4 /
Apoe / cells. In Nox4 /Apoe / SMCs, silencing of Nox1 sig-
nificantly increased the expression of SM-α-actin in high glucose
conditions only, with Nox4þ /þApoe / SMCs being unaffected
(Fig. 6D). In Nox4þ /þApoe / SMCs, silencing of NOX1 reduced
fibronectin and collagen I (Supplemental Fig. 3A and B) expression
but was unable to modulate the elevated expression of these ECM
genes observed in the Nox4 /Apoe / SMCs. In contrast, pro-
liferation genes Ki67 and PCNA (Supplemental Fig. 3C and D) were
reduced in both Nox4þ /þApoe / and Nox4 /Apoe / cells si-
lenced for NOX1. Therefore, NOX1-derived ROS are important
mediators of PDGF and OPN expression as well as downstream
proliferation pathways in SMCs that lack NOX4.
3.7. Inhibition of PDGF reverses aberrant expression of calponin,
Fig. 6. Silencing of NOX1 attenuates the aberrant expression of NOX1, PDGF-BB, osteopontin (OPN), and SM-α-actin genes in NOX4-deficient SMCs. (A) NOX1, (B) PDGF-BB,
(C) OPN, and (D) SM-α-actin mRNA levels relative to 18S in Nox4þ /þApoe / (filled bars) and Nox4 /Apoe / (open bars) SMCs following knockdown with siRNA against
NOX1. Values are mean7SEM (n¼6). *po0.05.
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The potent and pleiotropic effects of PDGF on vascular SMC
pathophysiology are well characterised. In order to elucidate the
role of PDGF in the NOX4-mediated phenotypic switch of SMCs,
we performed inhibition experiments using a PDGF neutralising
antibody (67 μg/ml, for 24 h). To confirm efficacy of the neu-
tralising antibody, we treated Nox4þ /þApoe / cells with PDGF or
with PDGF neutralising antibody. In all cases, neutralising antibody
reversed the effect of PDGF, except for the contractility marker
calponin, which was elevated in Nox4þ /þApoe / SMCs treated
with inhibitor when compared to treatment with PDGF alone
(Fig. 7A). In Nox4 /Apoe / cells, inhibition of PDGF normalised
calponin (Fig. 7A) and PDGF expression levels (Fig. 7B). PDGF
treatment dramatically induced OPN expression in Nox4þ /
þApoe / SMCs, which was reversed by PDGF inhibition (Fig. 7C).
Conversely, the heightened expression of OPN in Nox4 /Apoe /
SMCs was unaffected by PDGF inhibition (Fig. 7C). In Nox4þ /
þApoe / SMCs, PDGF-induced fibronectin (Fig. 7D) and Collagen I
(Supplemental Fig. 4A) gene expression was prevented by in-
hibitor treatment. In Nox4 /Apoe / SMCs, only fibronectin ex-
pression was dampened by anti-PDGF (Fig. 7D). PDGF induced
proliferative gene expression in Nox4þ /þApoe / SMCs; however,
treatment with anti-PDGF was ineffective at reducing heightened
Ki67 and PCNA expression levels in Nox4 /Apoe / SMCs (Sup-
plemental Fig. 4B and C).
Previous studies have shown that ECM production and pro-
liferation of SMCs during neointimal formation is associated with
PDGF- induced ROS production by NOX1. Here we also observedinduction of Nox1 gene expression by PDGF in Nox4þ /þApoe /
SMCs cultured under HG conditions (Supplemental Fig. 4C).
Treatment of Nox4 /Apoe / SMCs with HG further increased
Nox1 mRNA levels, an effect which could be inhibited by the PDGF
neutralising antibody (Supplemental Fig. 4D). Importantly, basal
expression of NOX1 in Nox4þ /þApoe / or Nox4 /Apoe / SMCs
cultured under NG conditions was unaffected by anti-PDGF
treatment (Supplemental Fig. 4D).3.8. Treatment of NOX4-deficient SMCs with hydrogen peroxide
(H2O2) normalises aberrant expression of PDGF-BB, OPN and fi-
bronectin genes
Treatment of Nox4þ /þApoe / SMCs with HG reduced PDGF
expression whereas treatment with H2O2 had no effect. In con-
trast, treatment of Nox4 /Apoe / SMCs with H2O2 reduced
expression of PDGF in the setting of HG (Supplementary Fig. 5A).
Expression of OPN in Nox4þ /þApoe / cells was increased by HG
and reduced by H2O2 treatment (Supplementary Fig. 5B). Similarly,
heightened OPN levels in Nox4 /Apoe / cells were dramatically
reduced by H2O2 (Supplementary Fig. 5B). Treatment of Nox4þ /
þApoe / or Nox4 /Apoe / SMCs with H2O2 also reduced ex-
pression of fibronectin under HG conditions (Supplementary
Fig. 5C). These effects of H2O2 on Nox4 /Apoe / cells cultured
under HG conditions were also observed for Collagen I, Ki67, PCNA,
and Nox1 gene expression levels (Supplemental Fig. 5D-G).
Fig. 7. Inhibition of PDGF reverses aberrant expression of calponin, PDGF-BB and fibronectin in NOX4-deficient SMCs. Gene expression of (A) Calponin, (B) PDGF-BB,
(C) osteopontin (OPN), and (D) Fibronectin in SMCs derived from Nox4þ /þApoe / (filled bars) and Nox4 /Apoe / (open bars) following treatment with PDGF-BB (10 ng/
ml for 24 h, Nox4þ /þApoe / SMCs only) or PDGF neutralising antibody (anti-PDGF; 67 μg/ml for 24 h). Values are mean7SEM (n¼3). *po0.05.
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4.1. Downregulation of contractile SMC markers and concomitant
upregulation of PDGF-BB and osteopontin (OPN) in aortas from dia-
betic NOX4-deficient mice
Vascular NADPH oxidase (NOX) enzymes play a central role in
the normal and pathological responses of vascular smooth muscle
cells (SMCs) that underscore the development and progression of
vascular disease. Previous studies have identified NOX4-derived
ROS as important mediators of the contractile, differentiated,
‘healthy’ SMC phenotype [2]. Few studies have explored SMC dif-
ferentiation in vivo in response to changes in local environmental
cues including NOX-derived ROS, hyperglycaemia and growth
factors [15]. In this study, a marked reduction in the expression of
the contractility markers SM-α-actin and calponin was observed in
the aortas of diabetic Apoe / mice, which were further decreased
by genetic deletion of NOX4. Furthermore, SMCs isolated from the
aortas of NOX4-deficient Apoe / mice showed reductions in SM-
α-actin, calponin and transgelin expression thus supporting a clear
role for NOX4 in the maintenance of the differentiated SMC phe-
notype, particularly in the setting of hyperglycaemia.
SMC phenotypic transition is associated with a loss of smooth
muscle markers and a gain of markers of proliferative and syn-
thetic activity, including PDGF and OPN [15]. Increased expression
of PDGF and OPN was seen in the aortas from diabetic Apoe /mice that was exacerbated by deletion of NOX4. In contrast, HG
treatment of Nox4þ /þApoe–/ or Nox4 /Apoe / SMCs did not
increase PDGF expression. Interestingly, HG treatment decreased
PDGF expression in NOX4-expressing cells and only in NOX4-de-
ficient cells treated with H2O2. Redox regulation of growth factor
signalling has been shown previously for epidermal growth factor
(EGF) where oxidation of the extracellular environment activates
metalloproteinase-mediated shedding of EGF-like ligands [27].
Silencing of NOX1 attenuated PDGF expression in Nox4 /Apoe /
 SMCs cultured under NG conditions. PDGF is a known inducer of
NOX1 activity [28] and in these studies it was shown that inhibi-
tion of PDGF blunted basal and HG-induced Nox1 gene expression
in Nox4 /Apoe / SMCs. Similarly, EGF stimulation of the EGF
receptor has been shown to be upstream of NOX1 activation in
vascular SMCs [29]. Taken together, these data suggest a positive
feedback mechanism between NOX1 and PDGF expression. Inter-
estingly, HG induced NOX1 gene expression in Nox4 /Apoe /
but not Nox4þ /þApoe / cells, suggesting that NOX4-derived ROS
suppress the pathway through which glucose regulates NOX1. In
line with this finding, Gray et al. [9] also demonstrated that genetic
deletion of Nox4 prevented diabetes-induced Nox1 gene expres-
sion in the aortas of Apoe / mice. Overall, these findings suggest
that diabetes-induced PDGF gene expression is a combined effect
of hyperglycaemia and other factors, such as ROS.
4.2. NOX1-associated ROS regulate diabetes-induced expression of
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Lee et al. [23] have shown that PDGF-induced ROS production
by NOX1 controls SMC proliferation. In this study we showed that
elevated Nox1 gene expression in NOX4- deficient SMCs correlated
with heightened expression of proliferation markers PCNA and
Ki67 as well as accelerated cell growth under HG conditions. OPN
has also been reported to stimulate vascular SMC proliferation [30]
and increase in expression in response to diabetes [19]. Here we
show that deletion of NOX4 leads to enhanced diabetes- mediated
expression of OPN in the aortas of Apoe / mice. Interestingly,
NOX4-deficient SMCs displayed dramatic increases in OPN gene
expression while OPN protein was only elevated in the setting of
high glucose. Redox regulation of OPN was first described by Lyle
et al. [20] where H2O2 (50 μM for 6–18 h)-treated rat SMCs sti-
mulated OPN gene and protein expression. In these studies we
demonstrated that acute treatment of Apoe / mouse-derived
SMCs with H2O2 (100 μM for 4 h) or siRNA against NOX1 de-
creased OPN gene expression. These findings suggest that NOX1-
derived superoxide when converted to H2O2 drives OPN expres-
sion. Interesting work by Arnold and colleagues [31] showed that
H2O2 formed from the dismutation of superoxide produced by
NOX1 induces the expression of PDGF in addition to other cell
cycle and growth-related genes We propose that in the setting of
NOX4 deficiency, HG treatment elevates levels of superoxide
leading to localized increases of H2O2 sufficient to increase OPN
transcription and translation.
The OPN protein in rodents is frequently resolved by western
blot as a doublet [20]; however, it is not yet known whether this
due to transcriptional or post-translational modification of OPN. In
dendritic cells, these 2 bands of higher and lower molecular
weight proteins represent the secreted and intracellular forms,
respectively [32]. We have demonstrated by western blot and
immunocytochemistry that NOX4-deficient SMCs expressed more
of the lower molecular weight intracellular OPN. Furthermore,
global NOX4 deletion in vivo prevented the diabetes-mediated
release of OPN into the circulation. Further studies are required to
discern whether the two OPN forms have distinct biological
properties in vascular SMCs, with studies in immune cells pro-
posing a role for intracellular OPN in cytoskeletal rearrangement
and in signal transduction pathways [33]. Our data indicate that
NOX4 regulates the production and retention of OPN protein in
SMCs in part via upregulation of NOX1, which promotes a pro-
liferative and synthetic phenotype.
4.3. Increased expression of pro-fibrotic factors and extracellular
matrix (ECM) proteins in the NOX4-deficient SMCs
Phenotypically modulated SMCs are prominent synthesisers of
ECM in atherosclerotic lesions [34], but few studies have examined
the role of NOX4 in vascular SMC fibrotic responses. Previous
studies by Schurmann et al. [8] identified that upon deletion of
NOX4 there was increased fibrotic response within the aorta. Ad-
ditionally, Babelova et al. [35] demonstrated that deletion of NOX4
in various models of renal disease increased fibrotic responses. In
this present study, we identified deposition of the fibrillar col-
lagen, Collagen I, in the aorta was significantly greater in diabetic
mice lacking NOX4 when compared to their Nox4þ /þApoe /
counterparts. Similarly, NOX4-deficient SMCs displayed not only
increased expression of collagen I and fibronectin but also key pro-
fibrogenic factors, TGFβ and CTGF when compared to Nox4þ /
þApoe / controls. Elevated fibronectin expression in Nox4 /
Apoe / SMCs was reduced by PDGF inhibition but not by si-
lencing of NOX1. Interestingly, H2O2 treatment of Nox4 /Apoe /
SMCs cultured under HG conditions suppressed the secretion of
fibronectin and collagen I into the extracellular space. In contrastto our findings, studies in cardiac [36] and lung fibroblasts [37]
showed that NOX4 induced TGFβ-mediated fibrosis. While it is
known that TGFβ increases NOX4 expression and activity [38] in
VSMCs, few studies have examined the reciprocal effect of NOX4-
derived ROS on fibrotic gene expression in this cell type; especially
in the context of diabetes. Here we have demonstrated NOX4-
mediated suppression of fibrotic responses in SMCs via PDGF and
H2O2. However, as NOX4 has been shown to be a driver of fibrosis
in epithelial models such as lung fibrosis models [39–41], one
cannot discount that NOX4 deletion is acting through different
mechanisms within this model.
Recent studies by Tong et al. [42] have explored the effects of
SMC-NOX4 on atherosclerosis induced by western diet and partial
left common carotid artery (LCA) ligation in FVB/N Apoe / mice
that overexpress a human dominant negative (DN) form of NOX4
specifically in SMCs. Contrary to the atherogenic effects previously
observed in C57/Bl6J Apoe / mice with genetic deletion of Nox4
and rendered diabetic [9] or subjected to Western-diet with sub-
sequent partial LCA ligation [8], these authors showed an at-
tenuation of atherosclerosis in DN mice linked to reduced in-
flammation, proliferation and migration via downregulation of
soluble epoxide hydrolase 2. Of note, the proliferation assays
presented in Schurmann et al., were restricted to SMCs isolated
from FVB/N mice with the authors citing difficulties obtaining data
from Apoe-/- SMCs, which was possible in the current study. Fur-
thermore, the effects of the human DN construct on the en-
dogenous NOX1 isoform or major pro-proliferative factors, such as
Ki67, were not reported. Intriguingly, the reduction in athero-
sclerosis seen in DN mice was not mirrored by significant changes
in lesion SM-α-actin-positive cells and, if anything, the percentage
of ‘non-macrophage’ SM-α-actin-stained cells trended towards
reduction. This data may provide some continuity across the stu-
dies, whereby lack of NOX4 leads to a loss of expression of char-
acteristic SMC markers. It is increasingly apparent that the role of
NOX4 in the development of atherosclerosis is far more complex
than anticipated and that careful interpretation of results in the
context of animal model and experimental methodology is
required.
4.4. Diabetes and NOX4 modulate SMC phenotypic changes of direct
relevance to atherosclerotic disease
Based on these studies, we propose a novel mechanism for
NOX4-mediated SMC responses in normal and high glucose con-
ditions. SMCs lacking NOX4 no longer produce H2O2 in response to
HG. Reduced NOX4-dependent H2O2 levels result in increased
expression of PDGF, which subsequently reduces calponin and
increases fibronectin gene expression. Under NG conditions,
NOX4-deficient SMCs showed increased PDGF independent of
changes in H2O2 and increased Nox1 expression independent of
PDGF but regulated in part by H2O2. Under HG conditions, PDGF
induces NOX1 expression that is associated with elevated super-
oxide levels and downstream induction of osteopontin expression
in addition to the proliferation genes Ki67 and PCNA. Taken to-
gether, these findings demonstrate a central role for NOX4 in the
suppression of vascular SMC proliferation and fibrosis, responses
that define the de-differentiated SMC phenotype associated with
the accelerated progression of atherosclerosis, as seen in diabetes.Disclosure
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